The effect of HIV treatment on HPV risk; bone mineral density declines in women vs. men; how hep C cure affects kidney function; when it comes to non-daily PrEP, location matters.
The risks of multiple non-HIV medication prescriptions; PrEP use and sexually transmitted infection incidence; how vaginal bacteria relate to HIV seroconversion; the effect of early treatment on HIV in the brain.
Gauging treatment priority when CD4 count is high; the effect of hepatitis C coinfection on response to HIV treatment; HIV, aging and comorbidity in Africa; PrEP and drug-resistant gonorrhea.
NeuroAIDS while on efavirenz vs. common NRTIs; HIV and the smoking cessation aid varenicline; PrEP adherence after positive partners start treatment; and Ugandans underreporting their antiretroviral use.
Our latest jaunt through HIV journals looks at a symptom-based scoring system to predict acute HIV, the effect of a person's sex on psychomotor function, and the value of vitamin D supplementation to moderate lipid levels.
In our final installment of 2017, we intermingle forward-looking research with some retrospective analysis. We begin our four-study tour by joining researchers in Tennessee for an exercise in HIV outbreak prediction.
Among this week's selection of four studies, we learn about data from a large study exploring the relative durability of first-line antiretroviral regimens stratified by drug class. (Spoiler alert: Older protease inhibitors don't do so well.)